H1N1 TREATMENT US

AMARILLO, TX–(Marketwire – February 16, 2010) – Amarillo Biosciences, Inc. (ABI) ( OTCBB : AMAR ) today announced additional preliminary results from the recently completed Phase 2 clinical trial conducted in Perth, Australia at the University of Western Australia with Professors David Smith and Manfred Beilharz as principal investigators.

Here is the original post:
Amarillo Biosciences Announces Australian Phase 2 Oral Interferon Clinical Trial Indicates Benefit in Preventing … (Marketwire)

Resistance to oseltamivir of pandemic ( H1N1 ) 2009 virus will compromise its use in treatment and render the billion-dose stockpile useless. Although the recently detected oseltamivir-resistant pandemic ( H1N1 ) 2009 virus in Hong Kong was …

See original here:
CIENCIASMEDICASNEWS: Oseltamivir- and Amantadine-Resistant …

Q: Recently, “a flow” epidemic developed rapidly in the right light the distinction between cases of severe disease and medical treatment ?Beijing C.

See more here:
“H1N1″ the four questions | H1N1 Care | H1N1 Influenza Virus

LETTER Recently, there has been some urgency by the Ministry of Health to purchase vaccines for the influenza A H1N1 pandemic, in view of the threat of a second phase.

Read more:
Doctors cautious over A H1N1 vaccines (Sin Chew Jit Poh)